StockNews.com assumed coverage on shares of Caladrius Biosciences (NASDAQ:CLBS – Get Rating) in a research report issued on Tuesday. The brokerage set a “sell” rating on the biotechnology company’s stock.
A number of other research firms have also recently commented on CLBS. HC Wainwright decreased their target price on shares of Caladrius Biosciences from $8.00 to $6.00 and set a “buy” rating on the stock in a research note on Wednesday, March 23rd. Zacks Investment Research upgraded shares of Caladrius Biosciences from a “hold” rating to a “buy” rating and set a $0.50 price objective on the stock in a research report on Tuesday, May 24th.
NASDAQ CLBS opened at $0.51 on Tuesday. Caladrius Biosciences has a 12 month low of $0.40 and a 12 month high of $1.68. The stock has a market cap of $31.11 million, a price-to-earnings ratio of -1.28 and a beta of 1.10. The company’s 50 day moving average is $0.57 and its two-hundred day moving average is $0.72.
Several institutional investors have recently added to or reduced their stakes in CLBS. Barclays PLC raised its position in shares of Caladrius Biosciences by 239.4% during the third quarter. Barclays PLC now owns 21,103 shares of the biotechnology company’s stock valued at $26,000 after buying an additional 14,885 shares during the last quarter. Two Sigma Securities LLC bought a new stake in shares of Caladrius Biosciences during the third quarter valued at approximately $33,000. Alterna Wealth Management Inc. bought a new stake in shares of Caladrius Biosciences during the fourth quarter valued at approximately $61,000. Goldman Sachs Group Inc. bought a new stake in shares of Caladrius Biosciences during the second quarter valued at approximately $87,000. Finally, Millennium Management LLC raised its position in shares of Caladrius Biosciences by 46.2% during the second quarter. Millennium Management LLC now owns 64,903 shares of the biotechnology company’s stock valued at $104,000 after buying an additional 20,498 shares during the last quarter. Hedge funds and other institutional investors own 18.76% of the company’s stock.
About Caladrius Biosciences (Get Rating)
Caladrius Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for the treatment of pre-dialysis patients with chronic kidney disease.
- Get a free copy of the StockNews.com research report on Caladrius Biosciences (CLBS)
- CrowdStrike earnings and revenue beat forecasts, stock falls
- Ryder System, Inc: The Most Interesting Play In Logistics
- This Isn’t A Buyable Bottom For Stocks
- Macys Stock is Ready to Buy
- First Solar Stock is Ready to Shine
Receive News & Ratings for Caladrius Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Caladrius Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.